DK2968461T3 - Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf - Google Patents
Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK2968461T3 DK2968461T3 DK14722439.8T DK14722439T DK2968461T3 DK 2968461 T3 DK2968461 T3 DK 2968461T3 DK 14722439 T DK14722439 T DK 14722439T DK 2968461 T3 DK2968461 T3 DK 2968461T3
- Authority
- DK
- Denmark
- Prior art keywords
- pdgf
- methods
- fusion proteins
- binding portions
- vegf binding
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780914P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/026872 WO2014160507A1 (en) | 2013-03-13 | 2014-03-13 | Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2968461T3 true DK2968461T3 (da) | 2022-12-19 |
Family
ID=50680144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14722439.8T DK2968461T3 (da) | 2013-03-13 | 2014-03-13 | Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9637534B2 (https=) |
| EP (1) | EP2968461B1 (https=) |
| JP (2) | JP6561042B2 (https=) |
| KR (1) | KR102228921B1 (https=) |
| CN (1) | CN105188733B (https=) |
| AR (1) | AR095437A1 (https=) |
| AU (2) | AU2014243712B2 (https=) |
| BR (1) | BR112015022208A8 (https=) |
| CA (1) | CA2904623A1 (https=) |
| DK (1) | DK2968461T3 (https=) |
| ES (1) | ES2933558T3 (https=) |
| FI (1) | FI2968461T3 (https=) |
| HR (1) | HRP20221447T1 (https=) |
| HU (1) | HUE060464T2 (https=) |
| IL (2) | IL240950B (https=) |
| LT (1) | LT2968461T (https=) |
| MX (1) | MX363533B (https=) |
| PL (1) | PL2968461T3 (https=) |
| PT (1) | PT2968461T (https=) |
| RS (1) | RS63820B1 (https=) |
| RU (1) | RU2692652C2 (https=) |
| SG (3) | SG10201912956YA (https=) |
| SI (1) | SI2968461T1 (https=) |
| TW (1) | TWI631133B (https=) |
| UY (1) | UY35407A (https=) |
| WO (1) | WO2014160507A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| CN105188733B (zh) | 2013-03-13 | 2020-05-08 | 建新公司 | 包含pdgf和vegf结合部分的融合蛋白及其使用方法 |
| US20160137717A1 (en) * | 2013-06-20 | 2016-05-19 | Gabriela Burian | Use of a vegf antagonist in treating choroidal neovascularisation |
| WO2015035342A2 (en) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Factor viii zwitterionic polymer conjugates |
| WO2015140638A1 (en) | 2014-03-18 | 2015-09-24 | Korea Advanced Institute Of Science And Technology (Kaist) | Glycosylated vegf decoy receptor fusion protein |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA2953698A1 (en) * | 2014-06-28 | 2015-12-30 | Kodiak Sciences Inc. | Dual pdgf/vegf antagonists |
| KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| MX2017008643A (es) | 2015-03-11 | 2018-04-26 | Allgenesis Biotherapeutics Inc | Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf). |
| WO2017001990A1 (en) | 2015-06-28 | 2017-01-05 | Allgenesis Biotherapeutics Inc. | Fusion proteins for inhibiting angiogenesis |
| WO2017084616A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| AU2017245143B2 (en) | 2016-03-30 | 2024-01-11 | Ab Biosciences, Inc. | Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| JP6849390B2 (ja) * | 2016-10-28 | 2021-03-24 | 花王株式会社 | 関節のこわばり改善剤 |
| US12043848B2 (en) * | 2017-10-16 | 2024-07-23 | Vigeneron Gmbh | AAV vectors |
| WO2019083171A2 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 큐로진생명과학 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물 |
| KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
| US11548931B2 (en) | 2017-11-16 | 2023-01-10 | Xl-Protein Gmbh | PASylated VEGFR/PDGFR fusion proteins and their use in therapy |
| CN111406071B (zh) * | 2017-11-16 | 2024-01-16 | 成都硕德药业有限公司 | Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途 |
| AU2019212622B2 (en) | 2018-01-26 | 2024-05-23 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| AU2020396699B2 (en) * | 2019-12-04 | 2024-07-18 | Cdmogen Co., Ltd | Composition for treating diabetic retinopathy, comprising rAAV containing soluble VEGFR-1 variant cDNA |
| CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
| CN112961250B (zh) * | 2021-03-01 | 2023-06-06 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
| CN113105558A (zh) * | 2021-04-01 | 2021-07-13 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法 |
| US20240285800A1 (en) * | 2021-06-18 | 2024-08-29 | Ikarovec Limited | Retinal Disorders |
| WO2023199951A1 (ja) * | 2022-04-13 | 2023-10-19 | 株式会社セルージョン | 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞 |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| CN119677771A (zh) * | 2022-08-02 | 2025-03-21 | 帕诺洛斯生物科技有限公司 | 经修饰的融合蛋白及其用途 |
| AU2024322540A1 (en) * | 2023-08-04 | 2026-03-05 | Panolos Bioscience, Inc. | Conjugate of modified fusion protein and scfv, and use thereof |
| WO2025042305A1 (ru) * | 2023-08-18 | 2025-02-27 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Нуклеотидная последовательность, кодирующпя слитый белок pdgfra-hfc |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4454151A (en) | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4952515A (en) | 1987-05-22 | 1990-08-28 | Polymer Technology International Corp. | Method of detection using a test strip having a non particulate dialyzed polymer layer |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| DK0584082T3 (da) | 1991-01-31 | 2000-10-16 | Univ California | Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider |
| US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
| US20030181531A1 (en) | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| AU2003218168A1 (en) | 2002-03-15 | 2003-09-29 | University Of Southern California | Ophthalmic solutions for delivery of expression vectors |
| US20040058313A1 (en) | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| PT2229956E (pt) * | 2004-09-13 | 2013-07-31 | Genzyme Corp | Contruções multiméricas |
| US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
| US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| DE102005020510A1 (de) | 2005-04-29 | 2006-11-09 | Basf Ag | Verbundelement, insbesondere Fensterscheibe |
| US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN101951925A (zh) * | 2008-02-20 | 2011-01-19 | 建新公司 | 血管发生抑制 |
| EP2604279A1 (en) * | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
| CN102311502B (zh) * | 2010-07-10 | 2013-12-25 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
| JP2014506119A (ja) * | 2010-12-02 | 2014-03-13 | ニューロテック ユーエスエー， インコーポレイテッド | 抗血管新生抗体足場および可溶性受容体を分泌する細胞株およびその使用 |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| CN102219859B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
| CN105188733B (zh) | 2013-03-13 | 2020-05-08 | 建新公司 | 包含pdgf和vegf结合部分的融合蛋白及其使用方法 |
-
2014
- 2014-03-13 CN CN201480026585.2A patent/CN105188733B/zh active Active
- 2014-03-13 WO PCT/US2014/026872 patent/WO2014160507A1/en not_active Ceased
- 2014-03-13 RS RS20221155A patent/RS63820B1/sr unknown
- 2014-03-13 US US14/210,354 patent/US9637534B2/en active Active
- 2014-03-13 MX MX2015011951A patent/MX363533B/es unknown
- 2014-03-13 FI FIEP14722439.8T patent/FI2968461T3/fi active
- 2014-03-13 BR BR112015022208A patent/BR112015022208A8/pt not_active IP Right Cessation
- 2014-03-13 SG SG10201912956YA patent/SG10201912956YA/en unknown
- 2014-03-13 SI SI201432005T patent/SI2968461T1/sl unknown
- 2014-03-13 ES ES14722439T patent/ES2933558T3/es active Active
- 2014-03-13 JP JP2016502268A patent/JP6561042B2/ja active Active
- 2014-03-13 KR KR1020157027849A patent/KR102228921B1/ko not_active Expired - Fee Related
- 2014-03-13 HU HUE14722439A patent/HUE060464T2/hu unknown
- 2014-03-13 UY UY0001035407A patent/UY35407A/es not_active Application Discontinuation
- 2014-03-13 TW TW103109211A patent/TWI631133B/zh not_active IP Right Cessation
- 2014-03-13 SG SG11201506802SA patent/SG11201506802SA/en unknown
- 2014-03-13 PL PL14722439.8T patent/PL2968461T3/pl unknown
- 2014-03-13 RU RU2015142999A patent/RU2692652C2/ru active
- 2014-03-13 LT LTEPPCT/US2014/026872T patent/LT2968461T/lt unknown
- 2014-03-13 AU AU2014243712A patent/AU2014243712B2/en active Active
- 2014-03-13 HR HRP20221447TT patent/HRP20221447T1/hr unknown
- 2014-03-13 EP EP14722439.8A patent/EP2968461B1/en active Active
- 2014-03-13 AR ARP140100983A patent/AR095437A1/es unknown
- 2014-03-13 PT PT147224398T patent/PT2968461T/pt unknown
- 2014-03-13 CA CA2904623A patent/CA2904623A1/en not_active Abandoned
- 2014-03-13 DK DK14722439.8T patent/DK2968461T3/da active
- 2014-03-13 SG SG10201707501TA patent/SG10201707501TA/en unknown
-
2015
- 2015-08-31 IL IL240950A patent/IL240950B/en active IP Right Grant
-
2017
- 2017-03-28 US US15/471,725 patent/US10183983B2/en active Active
-
2018
- 2018-11-20 US US16/197,194 patent/US11084864B2/en active Active
- 2018-12-12 AU AU2018278902A patent/AU2018278902A1/en not_active Abandoned
-
2019
- 2019-02-04 JP JP2019017599A patent/JP2019123711A/ja active Pending
- 2019-05-19 IL IL266715A patent/IL266715A/en unknown
-
2021
- 2021-07-02 US US17/367,027 patent/US20220064262A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2968461T3 (da) | Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf | |
| DK3356413T3 (da) | Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf | |
| DK3280727T3 (da) | Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf | |
| DK2999103T3 (da) | Konverter og fremgangsmåde til styring deraf | |
| DK3275895T3 (da) | Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf | |
| DK3390444T3 (da) | Anti-tl1a-antigenbindende proteiner og anvendelser deraf | |
| DK3744835T5 (da) | Dna modificerende fusionsproteiner og metoder til anvendelse deraf | |
| DK3581207T3 (da) | Fusionsproteiner omfattende hoxd12 og nemo-bindingsdomæne og anvendelse deraf | |
| DK3017286T3 (da) | Fremgangsmåde, kit og system til billeddannelse af en blodprøve | |
| HUE058280T2 (hu) | Leptin-receptort aktiváló antigénkötõ fehérjék | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| PL3068954T3 (pl) | Hangar, element łukowy oraz zastosowanie hangaru | |
| DK3083680T3 (da) | Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| DK3697090T3 (da) | Billedafkodningsindretning, billedafkodningsfremgangsmåde og billedafkodningsprogram | |
| DK3322734T3 (da) | Multivalente og multispecifikke DR5-bindende fusionsproteiner | |
| DK3265123T5 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| DK3290441T3 (da) | Rgma-bindingsprotein og anvendelse deraf | |
| DK3380119T3 (da) | Fmdv- og e2-fusionsproteiner og anvendelser deraf | |
| EP3738976C0 (en) | IL-17A-BINDING FUSION PROTEIN | |
| DK3060922T3 (da) | Fremgangsmåde og anordning til proteinfremstilling | |
| DK3271453T3 (da) | Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser | |
| DK2983704T3 (da) | Fusionspolypeptider og vacciner | |
| DK2894818T3 (da) | Kontrolmetode i software-definerede netværk, styreanordning og processor |